Intravenous Iron Therapy: Re-administration after Prior Adverse Reaction
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Intravenous (IV) iron therapy is performed in community practices and hospitals with modern for-mulations when oral administration becomes impractical. Effective replacement of iron is important for the treat-ment of iron deficiency and anemia. Can IV iron be rechallenged in individuals with a history of adverse reactions? This review is to explore the challenge of this, when clinically indicated.Methods: After performing a literature search, five studies (combined total sample number=1,006) for re-exposure of IV iron to individuals with a history of past reactions were identified, observed, and analyzed. Re-exposure in-cluded reactions ranging from mild to moderate and few cases of severe type.Results: The majority (>80%) of IV iron rechallenges were tolerable, safe, and successful without major serious inci-dents. There were no reports of major reactions (severe hypersensitivity reactions or anaphylaxis) in these re-expo-sures.Conclusion: Re-administration of IV iron therapy in patients with a previous adverse reaction is plausible, with benefit and risk stratification. A rechallenge would depend on the nature and degree of the adverse reaction and use of alternative formulations. Rechallenge to a previous severe hypersensitivity reaction or anaphylaxis with the same product has not been reported in these studies. Evidence on the benefit of premedication use is conflicting and requires further studies.
Abstract
Background: Intravenous (IV) iron therapy is performed in community practices and hospitals with modern for-mulations when oral administration becomes impractical. Effective replacement of iron is important for the treat-ment of iron deficiency and anemia. Can IV iron be rechallenged in individuals with a history of adverse reactions? This review is to explore the challenge of this, when clinically indicated.Methods: After performing a literature search, five studies (combined total sample number=1,006) for re-exposure of IV iron to individuals with a history of past reactions were identified, observed, and analyzed. Re-exposure in-cluded reactions ranging from mild to moderate and few cases of severe type.Results: The majority (>80%) of IV iron rechallenges were tolerable, safe, and successful without major serious inci-dents. There were no reports of major reactions (severe hypersensitivity reactions or anaphylaxis) in these re-expo-sures.Conclusion: Re-administration of IV iron therapy in patients with a previous adverse reaction is plausible, with benefit and risk stratification. A rechallenge would depend on the nature and degree of the adverse reaction and use of alternative formulations. Rechallenge to a previous severe hypersensitivity reaction or anaphylaxis with the same product has not been reported in these studies. Evidence on the benefit of premedication use is conflicting and requires further studies.
참고문헌 (20)
- Aung T, "Intravenous iron infusion and newer non-dextran formulations", N Z Med J, 134, pp.118~127 (2021)
- Blumenstein I, "Newer formulations of intravenous iron : a review of their chemistry and key safety aspects : hypersensitivity, hypophosphatemia, and cardiovascular safety", Expert Opin Drug Saf, 20, pp.757~769 (2021)
- Arastu AH, "Analysis of adverse events and intravenous iron infusion formulations in adults with and without prior infusion reactions", JAMA Netw Open, 5, pp.e224488~ (2022)
- Avni T, "The safety of intravenous iron preparations : systematic review and meta-analysis", Mayo Clin Proc, 90, pp.12~23 (2015)
- Wang C, "Comparative risk of anaphylactic reactions associated with intravenous iron products", JAMA, 314, pp.2062~2068 (2015)
- Dave CV, "Risks for anaphylaxis with intravenous iron formulations : a retrospective cohort study", Ann Intern Med, 175, pp.656~664 (2022)
- Cardona V, "World allergy organization anaphylaxis guidance 2020", World Allergy Organ J, 13, pp.100472~ (2020)
- Wolf M, "Randomized trial of intravenous iron-induced hypophosphatemia", JCI Insight, 3, pp.e124486~ (2018)
- Fishbane S, "The safety of intravenous iron dextran in hemodialysis patients", Am J Kidney Dis, 28, pp.529~534 (1996)
- Lim W, "Canadian expert consensus : management of hypersensitivity reactions to intravenous iron in adults", Vox Sang, 114, pp.363~373 (2019)
- Auerbach M, "Single-dose intravenous iron for iron deficiency : a new paradigm", Hematology Am Soc Hematol Educ Program, 2016, pp.57~66 (2016)
- Stojanovic S, "Safety of intravenous iron following infusion reactions", J Allergy Clin Immunol Pract, 9, pp.1660~1666 (2021)
- Steveling-Klein EH, "Management of hypersensitivity reactions to nondextran iron products : new insights into predisposing risk factors", J Allergy Clin Immunol Pract, 9, pp.2406~2414 (2021)
- Morales Mateluna CA, "Approach to hypersensitivity reactions from intravenous iron preparations", Allergy, 72, pp.827~830 (2017)
- Wesstrom J, "Safety of intravenous iron isomaltoside for iron deficiency and iron deficiency anemia in pregnancy", Arch Gynecol Obstet, 301, pp.1127~1131 (2020)
- (2013)[URL]
- Gomez-Ramirez S, "Prevention and management of acute reactions to intravenous iron in surgical patients", Blood Transfus, 17, pp.137~145 (2019)
- Richards T, "Questions and answers on iron deficiency treatment selection and the use of intravenous iron in routine clinical practice", Ann Med, 53, pp.274~285 (2021)
- Rampton D, "Hypersensitivity reactions to intravenous iron : guidance for risk minimization and management", Haematologica, 99, pp.1671~1676 (2014)
- Choo KJ, "Glucocorticoids for the treatment of anaphylaxis : Cochrane systematic review", Allergy, 65, pp.1205~1211 (2010)